Worrisome discovery—Among placebo group for Novavax’s vaccine in South Africa🇿🇦: people with prior #COVID19 infections appeared just as likely to get sick as people without prior infections—means past infection wasn’t fully protective for #B1351 variant.🧵 washingtonpost.com/health/2021/02…
2) The #B1351 has swiftly become dominant in South Africa, but has been found worldwide. The variant has been detected only a handful of times in the United States, including a case reported Friday in Virginia—3rd US state to identify the presence of the #B1351 variant.
3) The preliminary finding from the 🇿🇦 vaccine trial (placebo group), based on a data set with limitations, stirred debate and concern among researchers. Also notice how the #B1351 variant has become near “dominant” in South Africa? Not a coincidence.
4) Dr Fauci: “The data really are quite suggestive: The level of immunity that you get from natural infection — either the degree of immunity, the intensity of the immunity or the breadth of immunity — is obviously not enough to protect against infection with the mutant”
5) Fauci noted that a **vaccine is better than natural infection in protecting people**, calling it “a big, strong plug to get vaccinated”...
And reality check for people who may have assumed immunity because already been infected. (natural herd immunity advocates listen up!)
6) Digging into the data (placebo group only)—notice how the incidence of total #COVID19 was equal at 3.9% between people with prior infections (seropositive) vs not?
➡️Notice incidence of moderate/severe was ~same too! Prior infection had no protection for even severe COVID!
7) The good thing is that the Novavax vaccine was roughly equally ~50% effective (in South Africa 🇿🇦, higher elsewhere) against the virus regardless of past infection (denoted as serostatus positive or negative in the figure). All the more reason to vaccinate.
8) Also notice how there was slightly higher efficacy of 60% in regular HIV negative patients in South Africa.
9) In the U.K. study of the Novavax vaccine (when #B117 was still ~half of all cases... the good old days), the Novavax vaccine had a good 89.3% efficacy. Much much higher than the ~50% in South Africa 🇿🇦 where #B1351 was dominant. novavax.com/sites/default/…
10) The Reinfection data shows the risks of a strategy to reach herd immunity pushed by Scott Atlas, adviser to President Donald Trump, who is said to have endorsed allowing the virus to spread mostly unfettered, while protecting nursing homes and other vulnerable populations.
11) The study backs up recent laboratory data from South African researchers analyzing blood plasma from recovered patients. 48% was completely unable to block the #B1351 pseudovirus in lab study. biorxiv.org/content/10.110…
12) Bottomline: #B1351 is a beast that increases the likelihood of reinfection for those who thought they had protection from prior #COVID19. Good news is vaccines do work & clearly work better than natural infection immunity (little to none against B1351). Vaccinate please.
13) ... we at @FAScientists warned previously about the likelihood that #B1351 (which has the bad E484K mutation) might be concerning for reinfection. Some dismissed this as “fearmongering” that it almost never happens. Yet we see this a lot now, which has gotten Fauci concerned.
2) Because the new and more contagious #B117 variant of the coronavirus is here. And it will dominate the US in a month, and dominate Florida in less than a month. Read:
Damnit, why Florida, why?!?! Don’t you know the new more infectious #B117 variant is spreading the fastest already in Florida? Doubling every 9 days there. #COVID19
2) The new #B117 will become dominant by March 8th if not sooner... doubling every 9 days.
BREAKING—South Africa 🇿🇦 halted use of the AstraZeneca-Oxford #COVID19 vaccine on Sunday after evidence emerged that it did not protect participants from mild or moderate illness caused by the #B1351 variant that was first seen there. 🧵 nytimes.com/live/2021/02/0…
2) Scientists in 🇿🇦 said on Sunday that a similar problem held among people who had been infected by earlier versions of #SARSCoV2: the immunity they acquired naturally did not appear to protect them from mild or moderate cases when reinfected by the variant, known as B.1.351.
3) Here was that finding in South Africa 🇿🇦 that the #B1351 variant is so evasive, people who survived #COVID19 and had immunity from it were NOT protected from reinfection— moreover, not even a little protected from severe disease either.
⚠️SURGING #B117 WITHIN US—growing 7% per day, doubling every 9.8 days nationally, & expected to become dominant by March 23rd. It is surging fastest in Florida—doubling every 9.1 days. Scientists are extremely worried: 35-45% more transmissible.🧵#COVID19 washingtonpost.com/health/ukvaria…
2) new preprint, led by @K_G_Andersen, “Our study shows that US is on a similar trajectory as other countries where B.1.1.7 rapidly became the dominant #SARSCoV2 variant, requiring immediate and decisive action to minimize #COVID19 morbidity and mortality” medrxiv.org/content/10.110…
3) Here is the current inferred number of #B117 cases in each state and in Florida and California, to Jan 30th.
FIRST ACTIVE DUTY DEATH FROM COVID—36 year old U.S. Air Force Tech Sergeant Michael Morris passed away from #COVID19 while stationed at Aviano NATO Base in Italy 🇮🇹. Morris is the first member of the U.S. Air Force to die of the virus while on active duty. nativenewsonline.net/currents/leech…
Almost 1 year ago, Feb 26, 2020, authors wrote in a top journal that the coronavirus posed “limited threat outside of China” & “wearing mask in public does not prevent people from getting” #COVID19
➡️We should have listened to the actual aerosol scientists instead on masks! 🤦🏻♂️
Meanwhile many in Asia — especially Japan 🇯🇵 South Korea 🇰🇷 and Taiwan 🇹🇼 (& China) recognized airborne transmission early because their aerosol experts led the way.
3) Meanwhile, a medical expert for all the top airlines in the world was quoted by Bloomberg to “forget face masks”. I highly doubt Dr David Powell of @IATA had any real expertise or experience in aerosol transmission or epidemiology.